Eli Lilly & Co., headquartered in Indianapolis, employs 43,000 staff and develops various pharmaceutical products, including diabetes, oncology, immunology, and neuroscience therapies, alongside radiopharmaceuticals through its subsidiary POINT Biopharma. The company manufactures and distributes products in the U.S., Europe, and Asia.
LLY has been in the news recently: Eli Lilly and Company announced that its experimental drug lepodisiran can reduce lipoprotein(a) levels by 93.9% after one injection, potentially lowering the risk of heart attacks and strokes for millions of Americans. This promising Phase 2 trial result highlights lepodisiran's potential impact on long-term cardiovascular health.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
